Skip to main content

Advertisement

Table 2 Univariate Kaplan–Meier (KM) and Cox proportional hazards (PH) models and multivariate Cox PH models for the 21 Chinese HCC patients in this study, HCC patients from Roessler et al. study, and HCC patients from Boyault et al. study

From: HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma

21 Chinese patients Recurrence (n = 21; 9 events)
HR (95 % CI) p value
Univariate Cox PH
 HBV pre-OLT (Yes, No) 0.285 (0.06, 1.48) 0.14
 Tumor grade (GI, GII GIII) 1.27 (0.63, 2.01) 4.50E−02
 Age (<49) 2.33 (0.62, 8.68) 0.21
 Gender (M, F) 0.29 (0.03, 2.47) 0.26
 HERC5 (Low, High) 10.34 (1.28, 83.55) 0.029
Univariate KM
 HERC5 (Low, High)   0.007
Multivariate Cox PH
 HERC5 (Low) 7.29 0.07
 HBV pre-OLT (Yes, No) 0.26 0.3
 Tumor grade 2.41 0.27
 Age (<49) 2.08 0.42
 Gender (M, F) 1.86 0.7
  1. Models indicate predictions of survival, PFS, or HCC recurrence with HERC5 mRNA expression and other relevant clinical factors
  2. Tumor grade is defined by American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010; TNM staging levels are defined by the TNM combinations corresponding to one of five stages (stages I–V)
  3. AVR-CC active viral replication chronic carrier, CC chronic carrier, No no HBV
Roessler et al. study Survival (n = 224; 86 events) Recurrence (n = 224; 125 events)
HR (95 % CI) p value HR (95 % CI) p value
Univariate Cox PH
 HBV (AVR-CC, CC, No) 1.32 (0.86, 2.03) 0.212 1.24 (0.86, 1.79) 0.26
 TNM Staging (I, II, III) 2.34 (1.77, 3.09) 2.18E−09 1.76 (1.41, 2.20) 7.81E−07
 Age (<50) 1.26 (0.84, 1.88) 0.262 1.01 (0.72, 1.42) 0.96
 Gender (M, F) 1.86 (0.09, 3.83) 0.0933 2.36 (1.24, 4.50) 0.009
 Cirrhosis (No, Yes) 0.20 (0.05, 0.80) 0.0227 0.50 (0.23, 1.07) 0.07
 HERC5 (Low, High) 1.79 (1.17, 2.74) 0.00706 1.55 (1.07, 2.24) 0.021
Univariate KM     
 HERC5 (Low, High)   0.0063   0.0198
Multivariate Cox PH     
 HERC5 (Low) 2.02 0.004 1.8 0.004
 Gender (M, F) 1.36 0.42 2.07 0.03
 Cirrhosis (No, Yes) 0.28 0.076 0.56 0.17
 Age (<50) 1 0.99 1.01 0.49
 HBV (AVR-CC, CC, No) 1.3 0.25 1.36 0.11
 TNM Staging (I, II, III) 2.32 1.06E−08 1.74 2.21E−06
  1. Models indicate predictions of survival, PFS, or HCC recurrence with HERC5 mRNA expression and other relevant clinical factors
  2. Tumor grade is defined by American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010; TNM staging levels are defined by the TNM combinations corresponding to one of five stages (stages I–V)
  3. AVR-CC active viral replication chronic carrier, CC chronic carrier, No no HBV
Boyault et al. study Survival (n = 41; 20 events) PFS (n = 41; 20 events)
HR (95 % CI) p value HR (95 % CI) p value
Univariate Cox PH
 HBV (Yes, No) 1.32 (0.51, 3.40) 0.57 1.02 (0.44, 2.38) 0.96
 Gender (M, F) 1.01 (0.34, 3.03) 9.88E−01 1.30 (0.49, 3.41) 6.01E−01
 Age (<65) 1.10 (0.45, 2.67) 0.85 1.48 (0.70, 3.17) 0.31
 HERC5 (Low, High) 2.69 (1.11, 6.51) 0.029 1.96 (0.95, 4.05) 0.07
Univariate KM     
 HERC5 (Low, High)   0.023   0.07
Multivariate Cox PH     
 HERC5 (Low) 3.31 0.018 3.8 0.01
 HBV (Yes, No) 1.28 0.63 1.16 0.78
 Gender (M, F) 1.22 0.74 1.32 0.64
 Age (<65) 1.02 0.42 1.02 0.4
  1. Models indicate predictions of survival, PFS, or HCC recurrence with HERC5 mRNA expression and other relevant clinical factors
  2. Tumor grade is defined by American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010; TNM staging levels are defined by the TNM combinations corresponding to one of five stages (stages I–V)
  3. AVR-CC active viral replication chronic carrier, CC chronic carrier, No no HBV